Page 1

August 12 , 2021 KIORA PHARMACEUTICALS EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update WALTHAM , Mass . , Aug. 12 , 2021 ( GLOBE NEWSWIRE ) -- EyeGate Pharmaceuticals , Inc. ( NASDAQ : EYEG ) , ( " EyeGate " or the " Company " ) , a clinical - stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases , today reported its financial results for the quarter ended June 30 , 2021 and provided an update on recent corporate and operational activities . " In the second quarter of 2021 we made significant advancements to build our business and our clinical initiatives remain on track as we enter this new phase of continued growth , ” said Brian Strem , Ph.D. , President and Chief Executive Officer of EyeGate . " We took important steps to advance our pipeline programs for PP - 001 and OBG , and we look forward to leveraging new opportunities to expand the therapeutic potential of our platform addressing a diverse range of ocular surface and systemic diseases . " Recent Business Highlights : Pipeline Updates Ocular Surface Franchise • PP - 001 is a first - in - class inhibitor of dihydroorotate dehydrogenase ( " DHODH " ) for ophthalmic indications . PP - 001 has been successfully formulated as a topical eye drop for conjunctivitis and dry eye disease ( " DED " ) . EyeGate successfully completed a Phase 1 safety study in healthy volunteers and upcoming expected milestones are as follows : 。 Hold a type B , pre - IND meeting with the U.S. FDA to discuss the path to initiating a Phase 2 clinical trial for patients with DED in Q3 2021 . 。 Report top - line data from the proof - of - concept study in Austria for patients with DED in Q4 2021 . • Ocular Bandage Gel ( " OBG " ) eye drop is based on a modified form of the natural polymer hyaluronic acid ( " HA " ) designed to protect the ocular surface , permit re- epithelialization of the cornea , and improve ocular surface integrity . Development of OBG has shifted from a medical device to a drug , which allows for Medicare Part D reimbursement . OBG is now in development to address ophthalmic conditions where epithelial cells are either missing ( wounds ) or compromised ( epitheliopathies ) . Upcoming expected milestones are as follows : 。 Initiate a proof - of - concept study in patients with persistent epithelial defects inQ4 2021 . Systemic Indications